Complete Genomics will receive $8 million to sequence 500 tumor/normal pairs, or $8,000 per genome, as part of a National Cancer Institute initiative funded by the American Recovery and Reinvestment Act of 2009, the company said this week. The project aims to identify therapeutic targets in childhood cancers.
The contract follows on a previous phase of the project, during which the company sequenced 50 tumor/normal pairs from pediatric cancers, including acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma, osteosarcoma, and Wilms tumor.
Complete Genomics originally mentioned the NCI contract during its second-quarter earnings call Aug. 4 (CSN 8/9/2011).
The project is part of NCI's Therapeutically Applicable Research to Generate Effective Treatments Initiative. For this, its second phase, Complete Genomics will focus on identifying somatic mutations associated with specific tumor types, and will submit the data to the TARGET database.